Search

Displaying results 5231 - 5240 of 9724 in total
  1. Drug

    Brigatinib

    go.drugbank.com/drugs/DB12267
    ApprovedInvestigational

    Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). … [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]

    Categories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  2. Drug

    Propiverine

    go.drugbank.com/drugs/DB12278
    Approved

    Propiverine is a widely used antimuscarinic drug with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB) [A32576]. … OAB has a negative impact on quality of life and may lead to leakage and inconvenient urinary accidents [L2327], [L2328].

    Products: PROPIVERIN AL 5MG, PROPIVERIN AL 15MG
  3. Drug

    Dasotraline

    go.drugbank.com/drugs/DB12305
    Investigational

    Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention

  4. Drug

    Chlorproguanil

    go.drugbank.com/drugs/DB12314
    Investigational

    It is a dichloro-derivative of chloroguanide.

  5. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive

    Categories: Monoamine Oxidase A Substrates
  6. Drug

    Samidorphan

    go.drugbank.com/drugs/DB12543
    ApprovedInvestigational

    , and a longer half-life, making it an attractive candidate for oral dosing. … [A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability

    Salts: Samidorphan L-malate
  7. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    Sparsentan is a dual antagonist of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II (Ang II) type 1 receptor (AT<sub>1</sub>R) with a similar affinity for both (9.3 nM for ET<sub … >A</sub>R and 0.8 nM for AT<sub>1</sub>R).

    Categories: Dual Endothelin Type A Receptor/Ang II Subtype 1 Receptor Antagonist (DEARA)
  8. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    to 3690 µmol/L [A33286]. … The presence of a PEG moiety in pegvaliase-pqpz allows a reduced immune response and improved pharmacodynamic stability [A33284].

  9. Drug

    Reproterol

    go.drugbank.com/drugs/DB12846
    Investigational

    Reproterol has been used in trials studying the treatment of Asthma, Exercise-Induced.

  10. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    maintenance monotherapy resulted in a 22% reduction in the risk of death. … [A260641] Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although with a 10-fold lower affinity compared to wild-type FLT3.